New research shows that weight loss from GLP-1 drugs like semaglutide doesn't happen all at once, but rather unfolds in three distinct stages, each with its own metabolic signature. Scientists at Vanderbilt University found that the body adapts differently during rapid weight loss, gradual decline, and weight maintenance phases, offering clues about why individual responses to these medications vary so widely. How Do GLP-1 Drugs Change Eating Behavior Over Time? Researchers at Vanderbilt conducted an extended study using mice treated with semaglutide for three weeks, measuring feeding behavior and energy expenditure continuously throughout and after treatment. This approach differed from most previous studies, which examined only short-term responses after a single dose or brief treatment window. The findings revealed something surprising about how these drugs reshape eating patterns. Rather than simply reducing overall food intake, semaglutide fundamentally reorganizes how and when people eat. The research identified distinct changes in meal size and meal frequency across the three weight loss stages: - Meal Size: Dropped sharply when treatment began and remained small throughout all three stages of weight loss and maintenance, never rebounding even as weight stabilized. - Meal Frequency: Initially decreased but then rebounded during the weight maintenance phase, meaning the body compensated for smaller meals by eating more often while keeping overall weight stable. - Rapid Regain: When semaglutide treatment ended, both meal size and meal frequency increased, corresponding with rapid weight regain of lost weight. "These drugs don't just make animals eat less overall, they fundamentally change how feeding behavior is organized. Meal size stays low, but over time the animals compensate by eating more frequently. That balance appears to be part of how weight loss eventually plateaus," said Julio Ayala, associate professor of molecular physiology and biophysics at Vanderbilt. Julio Ayala, Associate Professor of Molecular Physiology and Biophysics at Vanderbilt University What Happens to Your Metabolism During Each Stage of Weight Loss? Beyond behavioral changes, the Vanderbilt team examined how the body's energy expenditure and fuel source shifted across the three stages. One of the most striking findings challenged common assumptions about how these drugs work. Contrary to expectations, the total number of calories burned remained largely unchanged throughout semaglutide treatment. However, the type of fuel the body burned shifted dramatically. Early in treatment, mice burned more fat, which aligned with active weight loss. But as they transitioned into the weight maintenance stage, they shifted toward burning less fat and more carbohydrates, even though body weight remained stable. "This switch in fuel utilization was one of the more surprising findings. Even though body weight was stable, the underlying metabolism was still changing. That suggests the system is actively adapting to defend the new body weight," explained Ayala. Julio Ayala, Associate Professor of Molecular Physiology and Biophysics at Vanderbilt University This metabolic adaptation may help explain why weight loss eventually plateaus despite continued drug treatment, and why weight regain happens so rapidly once treatment stops. The body appears to be actively defending its new weight through metabolic shifts that occur independently of calorie burning. Why Do Some People Respond Better to GLP-1 Drugs Than Others? GLP-1 receptor agonists are known for their variability in real-world use. Some patients lose substantial amounts of weight, while others respond modestly or not at all. The Vanderbilt findings may offer insight into this heterogeneity. Understanding the behavioral and metabolic adaptations revealed in this study could help explain why individual responses differ so dramatically. If researchers can identify the mechanisms that drive these different stages and the transitions between them, they may be able to predict who will respond well to treatment and who might need alternative approaches. "If we can identify the mechanisms that drive these different stages, and the transitions between them, we may be able to understand why some individuals respond better than others. Ultimately, that could inform more personalized treatment strategies," noted Ayala. Julio Ayala, Associate Professor of Molecular Physiology and Biophysics at Vanderbilt University The research also underscores the importance of studying drug effects over extended periods. Short-term studies may capture only the initial phase of weight loss, missing the adaptive responses that shape long-term outcomes and individual variation in treatment response. What's Next for GLP-1 Research and Treatment? Building on these findings, Ayala's lab is now investigating how brain activity changes across the different stages of semaglutide-induced weight loss, maintenance, and regain. Because GLP-1 receptor agonists primarily act in the brain to suppress appetite, identifying stage-specific neural activity patterns is a critical next step in understanding how these drugs work. The team is also exploring molecular changes in peripheral tissues, such as liver, fat, and muscle, that may underlie the observed shift from fat to carbohydrate use during weight maintenance. These investigations could reveal new targets for improving treatment outcomes and reducing the rapid weight regain seen when patients stop taking the medication. Meanwhile, the FDA continues to expand treatment options. In March 2026, the agency approved Wegovy HD, a higher dose (7.2 mg) of semaglutide, under an expedited review process. Clinical data showed that the higher dose resulted in additional average weight reduction compared to previously approved doses, with a safety profile consistent with known side effects. The most common adverse reactions observed with the higher dose were gastrointestinal, including nausea, vomiting, diarrhea, constipation, and abdominal pain. Reports of altered skin sensation, described as sensitivity, pain, or burning, occurred more frequently at the higher dosage than lower dosages, though these generally resolved on their own or with dose reduction. As GLP-1 receptor agonists continue to reshape obesity treatment, research like the Vanderbilt study provides a deeper understanding of the biological complexity underlying their success and limitations. Recognizing that weight loss unfolds in distinct stages, each with its own biology, is essential for improving outcomes for patients and developing more personalized treatment approaches.
